ELI LILLY & Co LLY
Pharmaceutical Preparations · NYSE
Ingresos
$34.12B
+19.6% A/A
Ingresos netos
$5.24B
-16.1% A/A
Activos totales
$78.72B
+23.0% A/A
EPS
5.80
-15.9% A/A
Márgen neto 15.4%
Presentaciones
Advertisement
Estado de ingresos
| Período | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 FY |
|---|---|---|---|---|---|---|---|---|
| Revenues | $45.89B | $28.29B | $12.73B | $34.12B | $31.51B | $20.07B | $8.77B | $28.54B |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| R&D Expense | — | — | — | — | — | — | — | — |
| SG&A Expense | $7.96B | $5.22B | $2.47B | $7.40B | $6.17B | $4.07B | $1.95B | $6.44B |
| Interest Expense | — | — | — | — | — | — | — | — |
| Net Income (Loss) | $14.00B | $8.42B | $2.76B | $5.24B | $6.18B | $5.21B | $2.24B | $6.24B |
| EPS (Diluted) | 15.56 | 9.35 | 3.06 | 5.80 | 6.83 | 5.76 | 2.48 | 6.90 |
Balance general
| Período | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 FY |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $112.48B | $112.48B | $112.48B | $78.72B | $78.71B | $78.71B | $78.71B | $64.01B |
| Current Assets | $55.63B | $55.63B | $55.63B | $32.74B | $32.74B | $32.74B | $32.74B | $25.73B |
| Cash & Equivalents | $7.27B | $7.27B | $7.27B | $3.27B | $3.27B | $3.27B | $3.27B | $2.82B |
| Accounts Receivable | $17.76B | $17.76B | $17.76B | $11.01B | $11.01B | $11.01B | $11.01B | $9.09B |
| Inventory | $13.74B | $13.74B | $13.74B | $7.59B | $7.59B | $7.59B | $7.59B | $5.77B |
| PP&E (Net) | $24.68B | $24.68B | $24.68B | $17.10B | $17.10B | $17.10B | $17.10B | $12.91B |
| Goodwill | $5.90B | $5.90B | $5.90B | $5.77B | $5.77B | $5.77B | $5.77B | $4.94B |
| Current Liabilities | $35.23B | $35.23B | $35.23B | $28.38B | $28.38B | $28.38B | $28.38B | $27.29B |
| Accounts Payable | $5.38B | $5.38B | $5.38B | $3.23B | $3.23B | $3.23B | $3.23B | $2.60B |
| Long-Term Debt | — | — | — | — | — | — | — | $19.10B |
| Stockholders Equity | $26.54B | $26.54B | $26.54B | $14.27B | $14.19B | $14.19B | $14.19B | $10.77B |
Estado de flujo de efectivo
| Período | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 FY |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $13.59B | $4.75B | $1.67B | $4.24B | $6.34B | $2.63B | $1.17B | $7.59B |
| Investing Cash Flow | $-8.17B | $-5.19B | $-3.35B | $-7.15B | $-7.38B | $-3.38B | $-1.18B | $-3.76B |
| Financing Cash Flow | $666.00M | $135.00M | $1.38B | $3.50B | $1.46B | $1.24B | $-311.30M | $-5.41B |
| Stock Repurchases | $2.60B | $1.89B | $1.20B | $750.00M | $446.10M | $0 | $0 | $1.50B |
Empresas similares
AbbVie Inc.
ABBV
ABBOTT LABORATORIES
ABT
BRISTOL MYERS SQUIBB CO
BMY
JOHNSON & JOHNSON
JNJ
Merck & Co., Inc.
MRK
PFIZER INC
PFE
REGENERON PHARMACEUTICALS, INC.
REGN
VERTEX PHARMACEUTICALS INC / MA
VRTX
Aprende más
How to Find Any SEC Filing in Two MinutesCash-Flow Quality: Profit Is an Opinion, Cash Is a FactValuation Basics: P/E, P/S and What They Actually Tell YouDividends: How Companies Pay Shareholders and How to Read ThemHow to Read a 10-K Annual Report (Without Falling Asleep)Understanding Earnings Per Share (EPS)How to Read a Cash Flow StatementHow to Read a Balance SheetHow to Read an Income Statement
Los datos se obtienen de la base de datos pública EDGAR SEC de EE. UU. Este sitio no proporciona asesoramiento de inversión.